OncoFirm™ -B

OncoFirm™ -B

Rapid Test for Breast and Ovarian Cancer Detection

Overview:
OncoFirm™ -B is an advanced rapid diagnostic test developed by OncoFirm Diagnostics for the early detection of breast and ovarian cancers. Powered by proprietary lateral flow assay (LFA) technology, this test targets tumor-specific Thomsen-Friedenreich (TF) and Gal-GalNAc antigens, offering accurate, non-invasive cancer screening at the point of care.

Key Features:

• Biomarker Specificity: Detects overexpression of TF and Gal-GalNAc antigens in breast and ovarian tumors.
• Rapid Results: Provides clear and actionable results in under 15 minutes using blood, serum, or plasma samples.
• High Sensitivity and Specificity: Enhanced through gold nanoparticle conjugation and signal amplification technology.
• Digital-Ready: Compatible with mobile readers and secure health data integration platforms.
• Clinically Relevant: Designed to support early detection in high-risk populations and improve treatment timelines.

Clinical Applications:

• Early screening in asymptomatic women with family history or genetic predisposition (e.g., BRCA mutations)
• Diagnostic aid in oncology clinics and women’s health programs
• Supplement to mammography and imaging in underserved regions
• Integration into public and private cancer screening initiatives

Benefits for Healthcare Providers:

• Enables early intervention, improving treatment outcomes
• Reduces diagnostic gaps and enhances decision-making
• Streamlines workflow for women’s health clinics and oncology practices

Regulatory Status:
Currently CE-marked for use in approved international markets, with clinical trials underway in preparation for FDA submission.